• +1-646-491-9876
    • +91-20-67278686

    Search

    Encephalitis - Pipeline Review, H1 2017

    Encephalitis - Pipeline Review, H1 2017

    • Report Code ID: RW0001689447
    • Category Healthcare
    • No. of Pages 38
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Encephalitis - Pipeline Review, H1 2017, provides an overview of the Encephalitis (Central Nervous System) pipeline landscape.

    Encephalitis is an inflammation of the brain tissue. There are two main types of encephalitis: primary and secondary. Primary encephalitis occurs when a virus directly infects the brain and spinal cord. Secondary encephalitis occurs when an infection starts elsewhere in the body and then travels to brain. Causes include common viruses, childhood viruses, and arboviruses. Risk factors include age and weak immune systems. Symptoms include fever, headache, vomiting, stiff neck, coma and hallucinations. Treatment includes pain killers, corticosteroids, anticonvulsants and sedatives.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Encephalitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical, Discovery and Unknown stages are 6, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

    Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalitis (Central Nervous System).
    - The pipeline guide reviews pipeline therapeutics for Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Encephalitis (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Encephalitis (Central Nervous System).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Encephalitis - Overview
    Encephalitis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Encephalitis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Encephalitis - Companies Involved in Therapeutics Development
    Aeterna Zentaris Inc
    CEL-SCI Corp
    Prosetta Biosciences Inc
    Sage Therapeutics Inc
    Encephalitis - Drug Profiles
    Amphotericin B sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CEL-1000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    miltefosine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PAV-645 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pneumococcal (23-valent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Polyglactin 370 for Acute Encephalitis Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SAGE-718 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Viral Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VY-OZ - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Encephalitis - Dormant Projects
    Encephalitis - Product Development Milestones
    Featured News & Press Releases
    Dec 17, 2016: Profounda receives FDA orphan-drug designation for the Treatment of Primary Amebic Meningoencephalitis (PAM) with Miltefosine
    Aug 24, 2016: Orlando patient survives Primary Amebic Meningoencephalitis using Profoundas drug Impavido (miltefosine)
    Dec 15, 2015: U.S. Issues Patent on Corifungin
    Feb 26, 2013: National Institutes of Health Supports Acea’s Research
    Aug 22, 2011: Dr. James McKerrow, efficacy of Corifungin vs. Naegleria
    Aug 22, 2011: FDA Grants 2nd Orphan drug designation
    Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Encephalitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Encephalitis - Pipeline by Aeterna Zentaris Inc, H1 2017
    Encephalitis - Pipeline by CEL-SCI Corp, H1 2017
    Encephalitis - Pipeline by Prosetta Biosciences Inc, H1 2017
    Encephalitis - Pipeline by Sage Therapeutics Inc, H1 2017
    Encephalitis - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Encephalitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Aeterna Zentaris Inc
    CEL-SCI Corp
    Prosetta Biosciences Inc
    Sage Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//encephalitis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//encephalitis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//encephalitis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments